New imaging trial aims to solve brain tumor scan confusion

NCT ID NCT06319027

Recruiting now Knowledge-focused Sponsor: ECOG-ACRIN Cancer Research Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This phase II trial is testing whether advanced imaging techniques like DSC-MRI and PET scans can better distinguish actual tumor growth from treatment-related changes in people with newly diagnosed glioblastoma. The study will enroll 100 adults who are receiving standard treatment. Researchers hope these scans will provide more accurate information than standard MRI alone, helping doctors make better decisions about whether a patient's tumor is progressing or just reacting to therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fluciclovine F18 (a radioactive tracer for PET scans), gadolinium-chelate (MRI contrast agent)
What this could lead to: If successful, this could help doctors more accurately tell whether changes on brain scans after treatment are due to tumor growth or side effects of therapy, leading to better treatment decisions.
What could go wrong: This is a phase II study with only 100 participants, so results may not apply to all patients. The imaging techniques are still experimental and may not prove more useful than standard MRI.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA, IDH-WILDTYPE

Contacts and locations

Show contact details

Locations

Baptist MD Anderson Cancer Center
RECRUITING

Jacksonville, Florida, 32207, United States
Carolinas Medical Center/Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28203, United States
Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States

Contact Email: •••••@•••••
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Edwards Comprehensive Cancer Center
RECRUITING

Huntington, West Virginia, 25701, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact Email: •••••@•••••
Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Email: •••••@•••••
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
RECRUITING

Madison, Wisconsin, 53718, United States

Contact Email: •••••@•••••
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••
Wake Forest University Health Sciences
RECRUITING

Winston-Salem, North Carolina, 27157, United States
West Virginia University Healthcare
RECRUITING

Morgantown, West Virginia, 26506, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.